Type 1 diabetes mellitus (T1DM) is characterized by beta cell dysfunction which is induced mostly by autoimmune attack. The deterioration of beta cell function is an inevitable tendency in patients with T1DM, and it is widely believed that patients progress to beta cell function failure within 1-2 years. However, the high heterogeneity of beta cell function decline has been observed nowadays, that some patients progress fast, some progress slowly, and some are with fluctuant decline patterns.
Studies have proved that genetics, immunity, and clinical characteristics of patients such as age-onset and medical intervention play important roles in the decline pattern of beta cell function. Although understanding of the disease heterogeneity has been greatly improved, the underlying mechanisms still wait to be explored. And the integrity analyses of multifaceted biomarkers in the dynamic changes of beta cell function are absent, which may be potent in the precise medicine of T1DM.
Given the complexity of the disease, the subclassification of T1DM is necessary to profile the heterogeneity of the disease. Thereby, we create this special column hammering at promoting the understanding of heterogeneity of T1DM and achieving personal diagnosis and treatment in the near future.
This Research Topic aims to summarize the recent advances in heterogeneity of clinical phenotypes in type 1 diabetes and of beta cell deterioration in type 1 diabetes. Potential topics include, but are not limited to:
- Heterogeneity of clinical phenotypes in type 1 diabetes and the potential subclassifications of the disease
- Genetics determinants and risk models to predict heterogeneity of beta cell deterioration in type 1 diabetes
- Immunological factors related with heterogeneity of beta cell deterioration in type 1 diabetes
- Metabolic biomarkers correlated with heterogeneity of beta cell deterioration in type 1 diabetes
- Medical therapy influences on disease progression heterogeneity in type 1 diabetes
- Big data and artificial intelligence exerted in the subclassification and precise medicine of type 1 diabetes
- The relationships between beta cell function heterogeneity and the outcomes including diabetic complications, cancer, and death of patient with type 1 diabetes
We welcome the submissions of Original Research, Review and Mini Review.
Type 1 diabetes mellitus (T1DM) is characterized by beta cell dysfunction which is induced mostly by autoimmune attack. The deterioration of beta cell function is an inevitable tendency in patients with T1DM, and it is widely believed that patients progress to beta cell function failure within 1-2 years. However, the high heterogeneity of beta cell function decline has been observed nowadays, that some patients progress fast, some progress slowly, and some are with fluctuant decline patterns.
Studies have proved that genetics, immunity, and clinical characteristics of patients such as age-onset and medical intervention play important roles in the decline pattern of beta cell function. Although understanding of the disease heterogeneity has been greatly improved, the underlying mechanisms still wait to be explored. And the integrity analyses of multifaceted biomarkers in the dynamic changes of beta cell function are absent, which may be potent in the precise medicine of T1DM.
Given the complexity of the disease, the subclassification of T1DM is necessary to profile the heterogeneity of the disease. Thereby, we create this special column hammering at promoting the understanding of heterogeneity of T1DM and achieving personal diagnosis and treatment in the near future.
This Research Topic aims to summarize the recent advances in heterogeneity of clinical phenotypes in type 1 diabetes and of beta cell deterioration in type 1 diabetes. Potential topics include, but are not limited to:
- Heterogeneity of clinical phenotypes in type 1 diabetes and the potential subclassifications of the disease
- Genetics determinants and risk models to predict heterogeneity of beta cell deterioration in type 1 diabetes
- Immunological factors related with heterogeneity of beta cell deterioration in type 1 diabetes
- Metabolic biomarkers correlated with heterogeneity of beta cell deterioration in type 1 diabetes
- Medical therapy influences on disease progression heterogeneity in type 1 diabetes
- Big data and artificial intelligence exerted in the subclassification and precise medicine of type 1 diabetes
- The relationships between beta cell function heterogeneity and the outcomes including diabetic complications, cancer, and death of patient with type 1 diabetes
We welcome the submissions of Original Research, Review and Mini Review.
